Endothelial function after anthracycline treatment.

Completed

• Conditions: Endothelial dysfunction; 10019280; 10027656

• Registration Number: NL-OMON46659
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

- Female
- Age >=18 years
- Histological proven breast cancer
- Planned treatment: a chemotherapeutic regimen containing anthracyclines.

Exclusion Criteria

Patients who are unable to fasten 3 hours prior to the measurement
- Prior treatment with chemotherapy which contained anthracyclines, platinum derivates or bleomycin.
- Prior treatment with high dose chest radiation (i.e. >20Gy)
- Possible confounders on endothelial function
o Current smokers and patients who quitted smoking < 2 years ago.
o Patients with known vascular disease (e.g. symptomatic peripheral or coronary artery disease)
o Patients with Diabetes Mellitus

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Endothelial function is measured by reactive hyperemia index (RHI) with a<br /><br>peripheral arterial tonometry (PAT).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Demographics, cardiovascular risk factors, medical history, oncological<br /><br>treatment protocol will be obtained from the patient file which is used at the<br /><br>outpatient clinic.</p><br>